Surrozen (SRZN) Total Current Liabilities (2020 - 2026)
Surrozen (SRZN) posted quarterly Total Current Liabilities of $9.6 million for Q1 2026, down 9.61% year-over-year from $10.6 million in Q1 2025, and down 3.68% quarter-over-quarter from $9.9 million in Q4 2025.
Surrozen (SRZN) Total Current Liabilities (2020 - 2026) Analysis & Trends
Surrozen's Total Current Liabilities history runs 7 years deep, the most recent figure standing at $9.6 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 9.61% year-over-year to $9.6 million; the TTM figure through Mar 2026 stood at $9.6 million (down 9.61% YoY), while the FY2025 annual figure was $9.9 million, up 35.75% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $9.6 million, down from $9.9 million in the prior quarter.
- The five-year high for Total Current Liabilities was $10.6 million in Q1 2025, with the low at $5.7 million in Q2 2025.
- The 5-year median for Total Current Liabilities is $7.3 million (2024), against an average of $7.7 million.
- Peak annual rise in Total Current Liabilities reached 722.53% in 2022, while the deepest fall reached 30.99% in 2022.
- Surrozen's Total Current Liabilities stood at $9.7 million in 2022, then declined by 26.55% to $7.1 million in 2023, then advanced by 2.34% to $7.3 million in 2024, then jumped by 35.75% to $9.9 million in 2025, then declined by 3.68% to $9.6 million in 2026.
- Business Quant data shows SRZN's Total Current Liabilities at $9.6 million in Q1 2026, $9.9 million in Q4 2025, and $6.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | 9.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.01 Mn |
| Mar 31, 2026 | 9.57 Mn |
| Dec 31, 2025 | 9.93 Mn |
| Sep 30, 2025 | 6.53 Mn |
| Jun 30, 2025 | 5.74 Mn |
| Mar 31, 2025 | 10.58 Mn |
| Dec 31, 2024 | 7.32 Mn |
| Sep 30, 2024 | 6.12 Mn |
| Jun 30, 2024 | 5.98 Mn |
| Mar 31, 2024 | 6.18 Mn |
| Dec 31, 2023 | 7.15 Mn |
| Sep 30, 2023 | 6.67 Mn |
| Jun 30, 2023 | 6.45 Mn |
| Mar 31, 2023 | 7.79 Mn |
| Dec 31, 2022 | 9.73 Mn |
| Sep 30, 2022 | 8.65 Mn |
| Jun 30, 2022 | 8.52 Mn |
| Mar 31, 2022 | 8.12 Mn |
| Dec 31, 2021 | 13.57 Mn |
| Sep 30, 2021 | 12.54 Mn |